285 related articles for article (PubMed ID: 23598276)
1. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
[TBL] [Abstract][Full Text] [Related]
2. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
3. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
4. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
[TBL] [Abstract][Full Text] [Related]
5. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
6. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
[TBL] [Abstract][Full Text] [Related]
7. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
Michieli P; Di Nicolantonio F
Nat Rev Clin Oncol; 2013 Jul; 10(7):372-4. PubMed ID: 23712183
[No Abstract] [Full Text] [Related]
10. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
[TBL] [Abstract][Full Text] [Related]
11. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
Xi WH; Yang LY; Cao ZY; Qian Y
Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
Previdi S; Abbadessa G; Dalò F; France DS; Broggini M
Mol Cancer Ther; 2012 Jan; 11(1):214-23. PubMed ID: 22027690
[TBL] [Abstract][Full Text] [Related]
13. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.
Kim BJ; Kim YJ; Sohn SH; Kim B; Sul HJ; Kim HS; Zang DY
Invest New Drugs; 2020 Dec; 38(6):1633-1640. PubMed ID: 32361789
[TBL] [Abstract][Full Text] [Related]
14. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
15. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
[TBL] [Abstract][Full Text] [Related]
16. Off-target effects of c-MET inhibitors on thyroid cancer cells.
Zhou Y; Zhao C; Gery S; Braunstein GD; Okamoto R; Alvarez R; Miles SA; Doan NB; Said JW; Gu J; Phillip Koeffler H
Mol Cancer Ther; 2014 Jan; 13(1):134-43. PubMed ID: 24170771
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
[TBL] [Abstract][Full Text] [Related]
18. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
Rimassa L; Bruix J; Broggini M; Santoro A
Clin Cancer Res; 2013 Aug; 19(15):4290. PubMed ID: 23766362
[No Abstract] [Full Text] [Related]
19. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.
Michieli P; Basilico C; Pennacchietti S
Clin Cancer Res; 2013 Aug; 19(15):4291. PubMed ID: 23766360
[No Abstract] [Full Text] [Related]
20. Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.
Wu Y; Li Z; Zhang L; Liu G
Med Sci Monit; 2019 Oct; 25():7383-7390. PubMed ID: 31575848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
